Literature DB >> 11278155

Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.

E Cantor-Graae1, L G Nordström, T F McNeil.   

Abstract

The purpose of the current study is twofold: (a) to provide an overall synthesis of recent research on substance abuse in schizophrenia and (b) to present findings in a Swedish patient sample. Studies conducted since 1990 have found a wide range of abuse prevalence rates, with male gender and younger age as primary correlates. Less certainty exists regarding substance abuse as an independent risk factor for schizophrenia and its further impact on illness course. In a sample of 87 patients attending a psychiatric clinic in Malmö, lifetime prevalence of substance abuse was 48.3%, with abuse debut primarily preceding first contact for psychotic symptoms. Significant correlates of abuse were male gender, family history of substance abuse, and increased rates of hospitalization and criminality, with poorer outcome found in previous as well as current abusers. Alcohol abuse, either solely or in combination with other substances, was the main type of substance abuse. Although the specific factors (social, behavioural, genetic) that predispose schizophrenic patients to substance abuse remain unclear, the predominantly male profile of abusers might suggest a link between substance abuse and the poorer clinical outcome frequently observed, especially in male schizophrenic patients.

Entities:  

Mesh:

Year:  2001        PMID: 11278155     DOI: 10.1016/s0920-9964(00)00114-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  58 in total

1.  Injury risk and severity in a sample of Maryland residents with serious mental illness.

Authors:  Emma E McGinty; Susan P Baker; Donald M Steinwachs; Gail Daumit
Journal:  Inj Prev       Date:  2012-06-02       Impact factor: 2.399

Review 2.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 3.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 4.  GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.

Authors:  Erik I Charych; Feng Liu; Stephen J Moss; Nicholas J Brandon
Journal:  Neuropharmacology       Date:  2009-07-23       Impact factor: 5.250

5.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

6.  Cannabis use disorders in schizophrenia: effects on cognition and symptoms.

Authors:  Pamela DeRosse; Alyson Kaplan; Katherine E Burdick; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Res       Date:  2010-05-18       Impact factor: 4.939

7.  Test-retest reliability of self-report measures in a dually diagnosed sample.

Authors:  Jon M Houck; Alyssa A Forcehimes; Elisa T Gutierrez; Michael P Bogenschutz
Journal:  Subst Use Misuse       Date:  2012-10-25       Impact factor: 2.164

8.  Impact of Family History in Persons With Dual Diagnosis.

Authors:  Camille S Wilson; Melanie E Bennett; Alan S Bellack
Journal:  J Dual Diagn       Date:  2012-11-27

9.  Demographic and clinical correlates of substance abuse comorbidity in schizophrenia.

Authors:  Tapas K Aich; Vinod K Sinha; Christoday R J Khess; Shailja Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

10.  Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse.

Authors:  Thomas Wobrock; Alkomiet Hasan; Berend Malchow; Claus Wolff-Menzler; Birgit Guse; Nicolas Lang; Thomas Schneider-Axmann; Ullrich K H Ecker; Peter Falkai
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.